Table 5.
Association Between Zygosity at HLA Class II Loci and HCC Among Liver Cirrhotic Patients in the REVEAL-HBV Cohort in Taiwan
| HLA Zygosity | Cirrhotic HCC (n = 138) | Liver Cirrhosis (n = 201) | HR Adjusted for Age, Sex, and Principal Components (95% CI)a |
|---|---|---|---|
| Class II loci | |||
| Heterozygous at all loci | 69 (50.0) | 107 (53.2) | Ref. |
| Homozygous in at least 1 locus | 69 (50.0) | 94 (46.8) | 1.09 (.78–1.52) |
| Number of homozygous | |||
| 1 | 46 (33.3) | 70 (34.8) | 1.08 (.74–1.58) |
| 2 | 12 (8.7) | 14 (7.0) | 0.92 (.49–1.72) |
| 3 | 11 (8.0) | 10 (5.0) | 1.37 (.72–2.60) |
| P trend | .52 | ||
| HLA-DPB1 | |||
| Heterozygote | 87 (63.0) | 128 (63.7) | Ref. |
| Homozygote | 51 (37.0) | 73 (36.3) | 1.08 (.76–1.53) |
| HLA-DQB1 | |||
| Heterozygote | 106 (76.8) | 166 (82.6) | Ref. |
| Homozygote | 32 (23.2) | 35 (17.4) | 1.13 (.76–1.68) |
| HLA-DRB1 | |||
| Heterozygote | 118 (85.5) | 181 (90.0) | Ref. |
| Homozygote | 20 (14.5) | 20 (10.0) | 1.08 (.66–1.76) |
Data are No. (%).
Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; REVEAL-HBV, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus study.
aHRs and 95% CIs were estimated from Cox proportional hazards regression models with time-in-study as time scale and were adjusted for sex, age (in categories, 30–39, 40–49, 50–59, 60–79 years), and principal components. Follow-up started from the date of diagnosis of liver cirrhosis and censored at diagnosis of HCC, death, and end of follow-up (2016), whichever occurred first.